SCNX
Scienture Holdings, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$2.92
−13.10%Oct 13, 2026, 12:05 UTC
Scienture Holdings, Inc. reported unaudited preliminary Q3 2026 revenue of approximately $1.22 million, up 256% sequentially.
Source:Sep 30, 2026, 20:05 UTC
Scienture Holdings, Inc. announced a 1-for-25 reverse stock split of its common stock, expected to take effect before markets open on October 5, 2026, reducing shares outstanding from 41,064,146 to approximately 1,642,565.
Source:Aug 14, 2026, 12:08 UTC
Scienture Holdings reported Q2 2026 financial results with approximately 510% sequential revenue growth from Q1 2026, gross margin of about 97.7%, operating loss improved about 48% year-over-year to approximately $2.7 million, and net loss narrowed about 58% year-over-year to approximately $2.8 million.
Source:Aug 12, 2026, 12:05 UTC
Scienture Holdings announced the commercial launch of REZENOPY, the highest dose FDA-approved naloxone nasal spray, and fulfillment of initial purchase orders.
Jun 9, 2026, 12:05 UTC
Scienture secured formulary coverage for REZENOPY with a large national health plan and expanded its commercial team, with a commercial launch planned for mid-July.
Source: